Viewing a single comment thread. View all comments

altxrtr t1_j7k0mnj wrote

Reply to comment by Call_In_The_Bin in Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study by burtzev

Nope, Cassava Sciences’ simufilam has been shown to improve cognition, behavior and a range of biomarkers in mild AD patients. Currently in Phase 3.

1

_MonteCristo_ t1_j7keb1n wrote

A quick google shows that several papers regarding this have been retracted and there are several investigations into potential fraud ongoing.

6